Abstract
In living related liver transplantation (LRLT), the use of graft livers across ABO blood groups is unavoidable since the organ donor is usually one of the recipient's parents. This report presents our initial experiences with LRLT, focusing on ABO-incompatible cases. From June 1990 to May 1992, we successfully performed a series of 34 LRLT on children (15 males and 19 females) ranging in age from 7 months to 15 years. Overall recipient survival rates were 90% (25/28) in elective LRLT and 50% (3/6) in emergency LRLT. These cases were classified into three groups: ABO blood group-identical (n=21), compatible (n=10), and incompatible (n=3). The immunosuppressive regimen consisted of FK506 and low-dose steroids in the first two groups. In the incompatible cases, exchange transfusion was performed to decrease anti-A and/or-B antibody titers before LRLT, and prophylactic OKT3 was added to FK506 and steroids after LRLT. No significant difference in recipient and graft survifal was observed among the groups. In the identical group, no rejection episodes have been observed thus far. Rejection occurred in two out of the ten compatible cases. Among the incompatible cases, one recipient had mild rejection and was treated. The remaining two recipients have had no rejection episodes thus far. Although all three recipients had cytomegalovitus (CMV) infection, they were successfully treated with gancyclovir, and no lethal infection has developed in any of these cases. The present results suggest that graft livers from living related donors across ABO blood groups can function well with FK506, low-dose steroids, and prophylactic OKT3 without causing lethal complications.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alexander JW, First MR, Majeski JA, Munda R, Fidler JP, Morris MS, Suttman MP (1984) The late adverse effect of splenectomy on patient survival following cadaveric renal transplantation. Transplantation 37: 467–471
Esquivel CO, Fung JJ, Markus B, Iwatsuki S, Gordon RD, Makowka L, Marsh JW Jr, Tzakis AG, Todo S, Starzl TE (1987) OKT3 in the reversal of acute hepatic allograft rejection. Transplant Proc 19: 2443–2446
Fischel RJ, Ascher NL, Payne WD, Freese P, Stock P, Fasola C, Najarian JS (1989) Pediatric liver transplantation across ABO blood group barriers. Transplant Proc 21: 2221–2222
Gordon RD, Iwatsuki S, Esquivel CO, Tzakis AG, Todo S, Starzl TE (1986) Liver transplantation across ABO blood groups. Surgery 100: 342–348
Gugenheim J, Samuel D, Reynes M, Bismuth H (1990) Liver transplantation across ABO blood group barriers. Lancet 336: 519–523
Iwatsuki S, Rabin BS, Shaw BW Jr, Starzl TE (1984) Liver transplantation against T cell positive warm crossmatch. Transplant Proc 16: 1427
King H, Shumaker HB (1952) Splenic studies: susceptibility to infection after splenectomy performed in infancy. Ann Surg 136: 239–247
Matsuno N, Inoko H, Ando A, Nakatsuji T, Sato T, Itchikawa S, Sonoda T, Tsuji K (1990) Importance of DQB as an indicator in living-related kidney transplant. Transplantation 49: 208–212
Mazzaferro V, Esquivel CO, Makowka L, Belle S, Kahn D, Koneru B, Scantlebury VP, Steiber AS, Todo S, Tzakis AG, Starzl TE (1989) Hepatic artery thrombosis after pediatric liver transplantation: a medical or surgical event? Transplantation 47: 971–977
Millis JM, McDiarmid SV, Hiatt JR, Brems JJ, Colonna JO, Klein AS, Ashizawa T, Hart J, Lewin K, Goldstein LI, Levy P, Busuttil RW (1989) Randomized prospective trial of OKT3 for early prophylaxis of rejection after liver transplantation. Transplantation 47: 82–88
Oh CS, Stratta RJ, Fox BC, Sollinger HW, Belzer FO, Maki DG (1988) Increased infection as associated with the use of OKT3 for treatment of steroid-resistant rejection in renal transplantation. Transplantation 45: 68–73
Ozaki N, Ringe B, Bunzendahl H, Taki Y, Gubernatis G, Micheal O, Kuse ER, Kiuchi T, Yamauchi K, Takada Y, Yamaguchi T, Ozawa K, Pichlmayr R (1991) Ketone body ratio as an indicator of early graft survival in clinical liver transplantation. Clin Transplant 5: 48–54
Ozawa K, Uemoto S, Tanaka K, Kumada K, Yamaoka Y, Kobayashi N, Inamoto T, Shimahara Y, Mori K, Honda K, Kamiyama Y, Kim HJ, Morimoto T, Tanaka A (1992) An appraisal of pediatric liver transplantation from living relatives; initial clinical experiences in 20 pediatric liver transplantations from living relatives as donors. Ann Surg 216: 547–553
Reding R, White DJG, Davies H, Latinne D, Delepaut B, Lambotte L, Calne Y (1989) Effect of splenectomy on antibody rebound after plasma exchange. Transplantation 48: 145–146
Reding R, Veyckemans F, Ville de Goyet J de, Hemptinne B de, Carlier M, Obbergh LV, Moulin D, Reynaert M, Latinne D, Vraux H, Jamart J, Rahier J, Otte JB (1992) ABO-incompatible orthotopic liver allograft in urgent indications. Surg Gynecol Obstet 174: 59–64
Samuel D, Gillet D, Castaing D, Reynes M, Bismuth H (1989) Portal and arterial thrombosis in liver transplantation: a frequent event in severe rejection. Transplant Proc 21: 2225–2227
Shumaker NJ (1970) Serum immunoglobulin and transferrin levels after childhood splenectomy. Arch Dis Child 45: 114–117
Singh N, Dummer JS, Kusne S, Breinig MK, Armstrong JA, Makowka L, Starzel TE, Ho M (1988) Infections with cytomegalovirus and other herpes virus in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis 158: 124–131
Stevens LH, Emond JC, Piper JB, Heffron TG, Thistlethwaite JR Jr, Whitington PF, Broelsch CE (1992) Hepatic artery thrombosis in infants: a comparison of whole livers, reduced-sized grafts, and grafts from living related donors. Transplantation 53: 396–399
Stratta RJ, Shaefer MS, Cushing KA, Markin RS, Reed EC, Langnas AN, Pillen TJ, Shaw BW Jr (1992) A randomized prospective trial of acyclovir and immune globulin prophylaxis in liver transplant recipients receiving OKT3 therapy. Arch Surg 127: 55–64
Swinnen LJ, Costazo-Nordin MR, Fisher SG, O'Sullivan EJ, Johnson MR, Heroux AL, Dizikes GJ, Pifarre R, Fisher RI (1990) Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipient. N Engl J Med 323: 1723–1728
Tanaka K, Uemoto S, Tokunaga Y, Fujita S, Sano K, Yamamoto E, Kato H, Yamaoka Y, Ozawa K (1992) Living related liver transplantation. Transplant Proc 24: 2252–2253
Uemoto S, Tanaka K, Honda K, Tokunaga Y, Sano K, Kato H, Yamamoto E, Takada Y, Ozawa K (1993) Experience with FK506 in living related donor liver transplantation. Transplantation 55: 288–292
Yamaoka Y, Ozawa K, Tanaka A, Mori K, Morimoto T, Shimahara Y, Zaima M, Tanaka K, Kumada K (1991) New devices for harvesting a hepatic graft from living donor. Transplantation 52: 157–160
Author information
Authors and Affiliations
About this article
Cite this article
Tokunaga, Y., Tanaka, K., Fujita, S. et al. Living related liver transplantation across ABO blood groups with FK506 and OKT3. Transplant Int 6, 313–318 (1993). https://doi.org/10.1007/BF00335967
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00335967